Galderma targets December 3 board vote as $1.5bn ZO Skin Health acquisition approaches closing

Galderma Group AG (SIX: GALD), the Switzerland-listed dermatology company, has proposed the appointment of Rosalind Brewer and Petra Rumpf to its board of directors while announcing that Chief Financial Officer Luigi La Corte intends to leave the business for another professional opportunity. Announced on November 2, 2026, the changes will involve an extraordinary general meeting on December 3, when shareholders will vote on the proposed board appointments and an increase in the board’s maximum permitted membership from 10 to 11 directors. The announcement comes just six months after La Corte formally assumed the CFO position and shortly after Galderma raised its annual sales guidance following record nine-month revenue of $4.765 billion. Although the company has emphasized continuity and confirmed that La Corte will remain during the transition, the absence of an announced successor creates an important leadership consideration as Galderma prepares to complete its $1.5 billion acquisition of ZO Skin Health. The immediate question for investors is whether the proposed governance expansion and finance leadership transition can be managed without disrupting capital allocation, acquisition integration or the company’s existing growth trajectory.

Galderma Chief Executive Officer Flemming Ørnskov has indicated that the business remains focused on executing its integrated dermatology strategy and delivering its existing priorities. Management has positioned the proposed board appointments as an opportunity to introduce additional expertise spanning consumer businesses, healthcare, medical technology and life sciences.

The company has not disclosed a departure date for La Corte, identified his next employer or announced the appointment of a replacement CFO. It has confirmed that he will continue performing his existing responsibilities during the handover, with further details expected once succession arrangements are finalized.

The proposed board changes also include the departure of Sherilyn McCoy, who will step down after seven years because of conflicting obligations. Her departure and the two proposed appointments would increase the board’s membership from 10 to 11 if shareholders approve the necessary resolutions.

Why is Galderma proposing Rosalind Brewer and Petra Rumpf for its board of directors?

Galderma is seeking to expand the expertise available to its board as the company develops across three distinct but related markets: injectable aesthetics, dermatological skincare and therapeutic dermatology. Each business has different commercial characteristics, customer relationships and regulatory requirements, creating a need for oversight that spans both consumer-oriented products and prescription healthcare.

Rosalind Brewer brings experience managing large consumer-facing businesses and healthcare-related retail operations. She previously served as chief executive officer of Walgreens Boots Alliance, chief operating officer and group president of Starbucks Corporation, and president and chief executive officer of Sam’s Club, a division of Walmart.

Her professional background includes senior leadership positions at Kimberly-Clark Corporation and extensive experience overseeing international operations, customer-facing businesses and organizational change. Brewer has also served on several major corporate boards, including those of Amazon.com and Starbucks.

For Galderma, her experience could be relevant to expanding premium skincare brands, developing commercial distribution and managing businesses that serve both healthcare professionals and consumers. The company has increasingly emphasized the importance of its dermatological skincare portfolio, including Cetaphil and Alastin, while investing in new distribution opportunities.

Petra Rumpf would contribute a different set of capabilities associated with medical technology, digital transformation and healthcare industry operations. Her career includes executive positions at Straumann Group and Nobel Biocare, as well as consulting experience involving life sciences and technology businesses.

Rumpf has served as chair of Straumann Group since 2024, providing current experience overseeing a publicly traded medical technology company. Her background includes the development of international business units, acquisitions, digital business models and professional healthcare distribution.

The combination would potentially strengthen Galderma’s oversight of consumer engagement and healthcare-specific commercial development. However, neither appointment has taken effect, and shareholders must approve the nominations before Brewer and Rumpf become directors.

What does Luigi La Corte’s planned departure mean for Galderma’s financial leadership continuity?

La Corte’s decision to leave is notable because he only became Galderma’s chief financial officer on May 1, 2026. His appointment had been announced in February, with a transition period beginning in April as he prepared to succeed Thomas Dittrich.

Dittrich had served as Galderma’s CFO since October 2019, making his departure a substantial change in the company’s financial leadership. La Corte was recruited with more than 30 years of international experience across healthcare, pharmaceuticals and consumer businesses.

Before joining Galderma, he served as chief financial officer of Recordati from 2019 to 2025. His earlier career included finance leadership positions at GlaxoSmithKline, AstraZeneca and Pladis Food Group, along with experience at several multinational consumer and professional services organizations.

The November announcement confirms that La Corte has decided to pursue another significant opportunity. It does not identify disagreements with Galderma’s strategy, financial reporting or management as reasons for his decision, and no such explanation should be inferred from the relatively short tenure.

Nevertheless, replacing a CFO after approximately six months creates practical continuity requirements. The finance function must maintain responsibility for financial reporting, treasury management, investor relations and capital allocation while preparing for a new leadership transition.

The timing is particularly relevant because Galderma is in the process of acquiring ZO Skin Health and has recently updated its financial outlook. A successor will need to understand the group’s existing financing structure, investment commitments and commercial priorities.

Galderma has said La Corte will remain in his role during the transition, which should support continuity while a successor is identified. The company has not disclosed whether it intends to promote an internal candidate, recruit externally or establish an interim arrangement.

The next significant development will be confirmation of the new CFO and the effective handover date. That announcement will provide a clearer basis for evaluating the financial leadership structure entering 2027.

How does Galderma’s December 3 extraordinary general meeting change its board structure?

Galderma has scheduled a virtual extraordinary general meeting for December 3, 2026, at 14:00 Central European Time. Shareholders will be asked to consider the proposed election of Brewer and Rumpf and an amendment increasing the maximum number of directors permitted under the company’s articles of association.

The existing board has 10 members. With McCoy stepping down and two new directors proposed, approval of the resolutions would allow the board to operate with 11 members.

The nominees would serve until completion of the next annual general meeting, consistent with the company’s annual director election structure. Galderma’s next scheduled annual general meeting is April 21, 2027.

The company is also proposing Brewer’s individual election to the Compensation Committee. That responsibility would give her a role in reviewing executive compensation matters, including the relationship between remuneration policy, corporate performance and shareholder interests.

Executive compensation oversight is relevant for a company pursuing both organic growth and acquisitions. Remuneration arrangements can influence management priorities, including revenue expansion, profitability, capital efficiency and longer-term business development.

The proposed appointments do not involve a change in the chairmanship. Thomas Ebeling remains Galderma’s board chair, while Flemming Ørnskov continues to lead the executive management team.

Galderma has not announced a wider board restructuring or changes to its other committees in connection with the November proposals. The precise effect on committee composition and responsibilities will become clearer after the shareholder vote and any subsequent organizational decisions.

Why do the governance changes matter after L’Oréal expanded its involvement in Galderma?

Galderma’s board composition has already evolved during 2026 following changes in its shareholder structure. Earlier in the year, L’Oréal increased its investment in the dermatology group, leading to changes in representation on the board.

At the April annual general meeting, shareholders approved the appointment of Delphine Viguier-Hovasse and Samuel du Retail as directors representing L’Oréal’s interests. They replaced directors associated with the shareholder consortium previously led by EQT.

The earlier changes reflected Galderma’s transition into a more mature publicly traded company with a different institutional shareholder base. The latest proposals would introduce additional experience from major consumer businesses and medical technology rather than representing a newly announced ownership transaction.

L’Oréal’s relationship with Galderma is commercially relevant because the businesses operate within overlapping segments of skin health and beauty, although Galderma also develops prescription treatments and injectable aesthetics products outside conventional consumer cosmetics.

Board oversight must accommodate these different business activities while maintaining appropriate governance arrangements for all shareholders. The presence of shareholder representatives does not remove the responsibilities of the board towards Galderma as a whole.

Brewer’s consumer business experience and Rumpf’s medical technology background could broaden the range of perspectives available for strategic discussions. The company has not, however, identified specific operating initiatives or financial targets that would depend on either appointment.

The immediate governance milestone remains the December shareholder vote. Any longer-term benefit will depend on how effectively the board applies the proposed expertise to capital allocation, management oversight and strategy.

What do Galderma’s $4.765 billion nine-month sales and raised 2026 guidance reveal about the business?

Galderma’s leadership announcement follows strong financial performance during the first nine months of 2026. The company reported net sales of $4.765 billion for the period, representing 25.1% year-over-year growth at constant currency and 27.5% growth on a reported basis.

Sales increased from approximately $3.737 billion during the corresponding period of 2025, an absolute reported increase of $1.028 billion. Management attributed the improvement primarily to higher volumes, supported by a favorable product mix and growth across its principal business categories.

Third-quarter revenue reached approximately $1.632 billion, increasing 26.0% at constant currency from the corresponding prior-year period. The result demonstrates that strong demand continued beyond the first half rather than being concentrated in one reporting period.

Therapeutic Dermatology was the fastest-growing category. Nine-month sales increased 64.4% at constant currency to $1.347 billion, supported by expansion of Nemluvio and continued contributions from the established treatment portfolio.

Nemluvio alone generated $735 million in sales during the first nine months. This represents approximately 54.6% of Therapeutic Dermatology revenue and 15.4% of total group sales, illustrating the growing importance of the treatment within Galderma’s overall business.

Injectable Aesthetics generated $2.174 billion, increasing 13.2% at constant currency. Dermatological Skincare contributed $1.244 billion, up 16.2%, with demand supported by brands including Cetaphil and Alastin.

Following the performance update on October 22, management raised its full-year 2026 net sales growth guidance to 22.5% to 23.5% at constant currency, compared with the previous forecast of 19% to 21%.

Galderma also reaffirmed its expectation of a Core EBITDA margin of approximately 26% at constant currency. The guidance excludes the potential effects of the proposed ZO Skin Health acquisition, which has not yet completed.

The stronger commercial performance provides a favorable operating backdrop for the leadership changes. However, the company’s growth outlook does not eliminate the need for a stable finance function capable of managing investment, acquisition financing and financial reporting.

Why is the $1.5 billion ZO Skin Health acquisition an important test for Galderma’s incoming CFO?

On October 14, Galderma announced a definitive agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion. The proposed transaction is an all-cash acquisition, subject to customary adjustments, and will be financed through a combination of existing cash reserves and bank financing.

ZO Skin Health operates in physician-dispensed skincare, supplying products through dermatologists, medical spas and other professional channels. The business generated approximately $330 million in net sales during the 12 months ended June 2026.

Its products are sold through more than 16,500 physician, medical spa and online accounts across over 40 countries. The acquisition would expand Galderma’s exposure to premium skincare sold through healthcare professionals, complementing the existing Alastin portfolio.

The financial structure creates responsibilities extending beyond the transaction’s closing. Galderma must manage acquisition financing, integration expenditure and the impact of the additional business on its earnings and balance sheet.

Management expects the acquisition to be broadly neutral to Core earnings per share during the first full year after closing. It also anticipates that ZO Skin Health will be slightly dilutive to the group’s Core EBITDA margin in 2027 before reaching a margin broadly comparable with the group average from 2028.

Galderma has estimated integration and one-time costs of approximately $50 million to $60 million during the first two years following acquisition. These expenditures must be distinguished from the $1.5 billion enterprise value and from recurring operating expenses associated with the acquired business.

The acquisition is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions. It should therefore not yet be treated as completed or included as an established contribution to Galderma’s reported sales.

The incoming CFO will need to oversee financial integration and maintain the company’s investment-grade financing profile. The leadership transition is consequently taking place at a commercially significant point in Galderma’s expansion strategy.

How strong is Galderma’s financial position heading into the CFO transition and acquisition?

Galderma’s first-half 2026 results provide the latest detailed public financial statements available for assessing profitability and leverage. The company reported net sales of approximately $3.134 billion, increasing 24.6% at constant currency compared with the previous year.

Core EBITDA reached $802 million, up from $555 million in the first half of 2025. The corresponding Core EBITDA margin increased to 25.6% from 22.7%, indicating improved profitability alongside higher revenue.

Reported net income increased to $444 million from $194 million. Operating profit reached $630 million, compared with $358 million a year earlier, reflecting a substantial improvement in the group’s earnings performance.

The balance sheet showed total indebtedness of approximately $2.625 billion at June 30, compared with $2.602 billion at the end of 2025. Cash and cash equivalents increased to $839 million from $780 million over the same period.

Total net indebtedness consequently declined to approximately $1.786 billion from $1.822 billion. These figures indicate that Galderma entered the second half with substantial liquidity and an improving earnings base.

However, the $1.5 billion ZO Skin Health transaction is expected to introduce additional financing requirements. The ultimate effect on net debt will depend on the combination of cash used, bank financing drawn and any changes in working capital or transaction expenses.

Galderma’s credit profile has also improved during 2026. S&P Global Ratings upgraded the company to BBB+, with the rating subsequently confirmed following the announcement of the ZO Skin Health acquisition.

The upgraded rating provides context for the company’s financing position, although it does not guarantee that future borrowing costs or credit assessments will remain unchanged.

A smooth CFO transition should support continuity in managing these obligations. The next major financial disclosure will provide updated information about earnings, debt and the effects of any completed acquisition.

How did Galderma shares react to the board proposals and CFO departure announcement?

Galderma shares entered November after a strong period of market performance. The stock closed at CHF 192.85 on October 30, compared with CHF 185.00 on October 27, representing an increase of approximately 4.2% across those three trading sessions.

During the November 2 session, delayed market quotations showed the shares trading around CHF 192.65, slightly below the preceding closing price. The reported intraday range was CHF 189.80 to CHF 193.45, indicating considerable variation during the day without establishing a sustained positive or negative reaction to the leadership announcement.

The stock had recently reached a 52-week high of CHF 193.90 on October 26, while its reported 52-week low stood at CHF 136.30 on March 23. The range illustrates the extent of Galderma’s share-price appreciation during 2026.

At approximately CHF 192.65 per share, the company’s equity market capitalization was around CHF 45.8 billion using approximately 237.9 million shares outstanding as reported by market data providers. This is an indicative valuation based on a delayed quotation rather than a confirmed November 2 closing capitalization.

The stock’s strong preceding performance reflects a period in which Galderma raised revenue expectations, expanded its therapeutic dermatology business and announced the ZO Skin Health acquisition. However, individual market movements cannot be attributed exclusively to those developments without additional evidence.

The CFO announcement introduces another factor for investors to evaluate. A departure so soon after appointment may prompt questions about succession and financial leadership stability, but it does not independently establish a problem with Galderma’s accounting, strategy or operating results.

The company’s share valuation increasingly reflects expectations for continued growth and profitability. Maintaining confidence in financial reporting, acquisition execution and future guidance will therefore be important as the management transition progresses.

What are the most important milestones for Galderma shareholders through early 2027?

The first governance milestone is the December 3 extraordinary general meeting. Approval of the proposed resolutions would expand the board to 11 members and appoint Rosalind Brewer and Petra Rumpf, with Brewer also taking a position on the Compensation Committee.

The second is confirmation of La Corte’s successor and the timetable for the finance leadership handover. Investors will need clarity about whether the replacement has experience managing multinational healthcare operations, acquisitions and public-market financial reporting.

The third major development is the planned completion of the ZO Skin Health acquisition. Galderma expects closing during the fourth quarter of 2026 or early 2027, after which the company will begin implementing its integration and commercial investment programme.

The timing of acquisition completion and CFO succession could overlap. Management has not said that the proposed departure will delay the transaction, and there is currently no basis for assuming that an interruption will occur.

Operationally, Galderma must deliver against its upgraded 2026 sales growth expectations and maintain profitability as its portfolio expands. The strong performance of Nemluvio and the wider Therapeutic Dermatology business has increased the importance of this category within the group.

The company is scheduled to report its full-year 2026 financial results on February 25, 2027. That announcement should provide more comprehensive evidence of profitability, cash generation, leverage and the contribution of commercial growth across its three categories.

For shareholders, the governance proposals provide additional board expertise, while the CFO transition introduces a near-term continuity requirement. The strongest evidence of successful management will be an orderly finance handover, completion of the planned board appointments and delivery of the company’s financial commitments without disruption to the ZO Skin Health acquisition or existing operations.

What are the key takeaways from Galderma’s board appointments, CFO transition and 2026 financial outlook?

• Galderma announced on November 2, 2026, that it is proposing Rosalind Brewer and Petra Rumpf for election to its board of directors.
• Shareholders will vote on the proposed appointments at a virtual extraordinary general meeting scheduled for December 3, 2026.
• Sherilyn McCoy will step down after seven years, while Galderma proposes increasing its maximum board size from 10 to 11 directors.
• Rosalind Brewer is also proposed for election to the Compensation Committee, subject to shareholder approval.
• Chief Financial Officer Luigi La Corte has decided to leave for another opportunity approximately six months after taking office on May 1.
• La Corte will remain during the transition, but Galderma has not disclosed a successor or confirmed departure date.
• Nine-month 2026 net sales reached $4.765 billion, increasing 25.1% year over year at constant currency, with Nemluvio contributing $735 million.
• Galderma raised its annual constant-currency sales growth guidance to 22.5% to 23.5% while maintaining a Core EBITDA margin target of approximately 26%.
• The company is preparing to complete its proposed $1.5 billion ZO Skin Health acquisition, which will require financial and operational integration.
• The principal upcoming milestones are the December shareholder vote, CFO succession announcement, acquisition closing and February 25, 2027 full-year financial results.